Teva CEO to retire
Executive Summary
Teva CEO Israel Makov, 67, will retire in 2007, he announces Oct. 18. Makov will be succeeded by Shlomo Yanai, who has served as CEO of Makhteshim Agan Industries since 2003. During Makov's tenure as CEO, Teva's sales increased four-fold to approximately $8.5 bil., and Teva became the world's largest generics manufacturer with the $7.8 bil. acquisition of Ivax (1"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.